Journal article · 2020

How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations

Marianne Botoft Hansen, Lotte Stig Nørgaard, Christine E. Hallgreen

Therapeutic Innovation & Regulatory Science, 54(3), 577–585 · Published 6 January 2020 · DOI 10.1007/s43441-019-00090-6

View at the publisherCite this paper

In brief

“How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations” is a 2020 journal article by Marianne Botoft Hansen and 2 co-authors, published in Therapeutic Innovation & Regulatory Science. OpenAlex counts 21 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
21
Most cited in
2022 (5)
Field-weighted impact
2.39
Authors
3

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Hansen, M. B., Nørgaard, L. S., & Hallgreen, C. E. (2020). How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations. Therapeutic Innovation & Regulatory Science, 54(3), 577–585. https://doi.org/10.1007/s43441-019-00090-6

MLA 9

Hansen, Marianne Botoft, et al. “How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations.” Therapeutic Innovation & Regulatory Science, vol. 54, no. 3, 2020, pp. 577–585. https://doi.org/10.1007/s43441-019-00090-6.

Chicago

Hansen, Marianne Botoft, Lotte Stig Nørgaard, and Christine E. Hallgreen. 2020. “How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations.” Therapeutic Innovation & Regulatory Science 54 (3): 577–585. https://doi.org/10.1007/s43441-019-00090-6.

Harvard

Hansen, M. B., Nørgaard, L. S. and Hallgreen, C. E. (2020) ‘How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations’, Therapeutic Innovation & Regulatory Science, 54(3), pp. 577–585. doi:10.1007/s43441-019-00090-6.

IEEE

M. B. Hansen, L. S. Nørgaard, and C. E. Hallgreen, “How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations,” Therapeutic Innovation & Regulatory Science, vol. 54, no. 3, pp. 577–585, 2020, doi: 10.1007/s43441-019-00090-6.

BibTeX

@article{hansen2020involve,
  title     = {{How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations}},
  author    = {Hansen, Marianne Botoft and Nørgaard, Lotte Stig and Hallgreen, Christine E.},
  journal   = {Therapeutic Innovation \& Regulatory Science},
  year      = {2020},
  volume    = {54},
  number    = {3},
  pages     = {577--585},
  doi       = {10.1007/s43441-019-00090-6},
  url       = {https://doi.org/10.1007/s43441-019-00090-6}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202022
202144
202255
202322
202433
202511
202644

Its field-weighted citation impact is 2.39: it has been cited 2.39 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Health Professions › General Health Professions › Mental Health and Patient Involvement

  • patient involvement
  • pharmaceutical industry
  • regulatory agencies
  • patient associations
  • stakeholder perspectives
  • barriers to patient involvement
  • trust and transparency
  • drug approval

Work with this paper

Most-cited papers in Health Professions

All highly cited Health Professions papers

Questions about this paper

How do I cite this paper in APA style?

Hansen, M. B., Nørgaard, L. S., & Hallgreen, C. E. (2020). How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations. Therapeutic Innovation & Regulatory Science, 54(3), 577–585. https://doi.org/10.1007/s43441-019-00090-6

How many times has this paper been cited?

21 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Marianne Botoft Hansen, Lotte Stig Nørgaard, Christine E. Hallgreen.

What is the DOI of this paper?

10.1007/s43441-019-00090-6, permanently at https://doi.org/10.1007/s43441-019-00090-6. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.